Literature DB >> 25122441

EGFR mutations in Asian patients with advanced lung adenocarcinoma.

Chong-Kin Liam1, Yong-Kek Pang, Mau-Ern Poh.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25122441     DOI: 10.1097/JTO.0000000000000251

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

1.  Antiproliferative Activity of a New Quinazolin-4(3H)-One Derivative via Targeting Aurora Kinase A in Non-Small Cell Lung Cancer.

Authors:  Ji Yun Lee; Huarong Yang; Donghwa Kim; Kay Zin Kyaw; Ruoci Hu; Yanhua Fan; Sang Kook Lee
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-02

Review 2.  Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review.

Authors:  Qianqian Zhang; Haiyang Liu; Jia Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-23       Impact factor: 6.055

3.  AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.

Authors:  Donghwa Kim; Duc-Hiep Bach; Yan-Hua Fan; Thi-Thu-Trang Luu; Ji-Young Hong; Hyen Joo Park; Sang Kook Lee
Journal:  Cell Death Dis       Date:  2019-05-01       Impact factor: 8.469

4.  Efficacy of Paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer.

Authors:  Yen-Han Tseng; Jen-Fu Shih; Heng-Sheng Chao; Yuh-Min Chen
Journal:  PeerJ       Date:  2019-09-24       Impact factor: 2.984

5.  A brief report on the mutational landscape in non-small cell lung cancer of South Asian patients: Comparison at a US and an Indian Institution.

Authors:  Mohana Roy; Amanjit Bal; Nalini Gupta; Kuruswamy T Prasad; Heather A Wakelee; Navneet Singh
Journal:  Lung India       Date:  2022 Jul-Aug
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.